Edition:
India

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

5.28EUR
19 Jan 2018
Change (% chg)

€0.01 (+0.19%)
Prev Close
€5.26
Open
€5.30
Day's High
€5.38
Day's Low
€5.25
Volume
270,169
Avg. Vol
376,488
52-wk High
€14.25
52-wk Low
€4.33

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.11
Market Cap(Mil.): €603.39
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

BRIEF-Eric Vivier Joins Innate Pharma As Chief Scientific Officer

* REG-WORLD RENOWNED IMMUNOLOGIST, PROFESSOR ERIC VIVIER, JOINS INNATE PHARMA AS CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Jan 2018

BRIEF-Innate Pharma provides an update on lirilumab

* ‍LIRILUMAB CONTINUES TO BE WELL-TOLERATED IN MONOTHERAPY AND IN COMBINATION ACROSS MULTIPLE TUMOR INDICATIONS

22 Nov 2017

BRIEF-Innate Pharma Q3 revenue up at 12.4 million euros

* Q3 REVENUE EUR 12.4 MILLION VERSUS EUR 11.2 MILLION YEAR AGO

15 Nov 2017

BRIEF-Innate Pharma reports IPH4102 final results of the dose-escalation part of the phase I study

* IPH4102: FINAL RESULTS OF THE DOSE-ESCALATION PART OF THE PHASE I STUDY

16 Oct 2017

BRIEF-Innate Pharma H1 operating loss widens to 18.2 million euros

* ‍CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS() FOR COMPANY AMOUNTED TO EUR 204.1M (MILLION EUROS) AS OF JUNE 30, 2017​

18 Sep 2017

BRIEF-New preclinical data further strengthen rationale of IPH5401 and Monalizumab

* REG-INNATE PHARMA : NEW PRECLINICAL DATA FURTHER STRENGTHEN THE RATIONALE OF IPH5401 AND MONALIZUMAB

11 Sep 2017

Earnings vs. Estimates